Search

What to expect

FacultyThe faculty is made up of international leaders in clinical hematology research, statisticians, experts in regulatory and ethical aspects of clinical research and more.

Acute Myeloid Leukemia

The AML SWG represents a group of national and internationally renowned clinical and research experts working in the field of AML.

‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda

Oct 06 2021

On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Navigate hematology

Building a career and a professional network can be overwhelming! Which career path should you take? How can you establish a meaningful mentoring relationship? Which funding is available and right for you? Who can you collaborate with? Is it time to publish?

On…

EHA Congratulates EHA Kick-Off Grant 2021 Winners

Jan 04 2022 Posted in Press releases

The Hague, January 3, 2022 –EHA Congratulates seven talented researchers in Hematology on their receipt of an EHA Kick-Off Grant 2021 after a rigorous selection process.